PAPERS AND SHORT REPORTS

Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminium hydroxide

R H K MAK, C TURNER, THEA THOMPSON, HELEN POWELL, G B HAYCOCK, C CHANTLER

Abstract

Secondary hyperparathyroidism was suppressed over a period of one year in 12 children with chronic renal failure by using a regimen of mild dietary phosphate restriction and high dose phosphate binders. The patients were randomised to receive either aluminium hydroxide or calcium carbonate by mouth for six months and then crossed over to the other medication. Vitamin D (dihydrotachysterol) dosage was unchanged. Serum parathyroid hormone concentrations were reduced to within the normal range, urinary cyclic adenosine monophosphate values fell, plasma phosphate concentrations decreased, and the theoretical renal phosphate threshold increased significantly. Transiliac bone biopsy findings improved in four patients with adequate suppression of parathyroid hormone concentrations, deteriorated in two patients who were not compliant, and did not change in five patients in whom initial bone disease was mild. Growth velocity improved significantly. There was no difference in the clinical response, biochemical changes, or incidence of complications during treatment with the two agents.

In view of the risk of aluminium toxicity the use of high dose calcium carbonate with dietary phosphate restriction and vitamin D supplementation is recommended in the control of secondary hyperparathyroidism in children with chronic renal failure.

Introduction

Secondary hyperparathyroidism is common in end stage renal disease and may cause disabling bone problems, growth retardation, and other complications.¹⁻³ Although the role of dietary phosphate in the pathogenesis of secondary hyperparathyroidism in experimental uraemia is well established,⁴⁻⁶ successful long term suppression of secondary hyperparathyroidism by dietary phosphate restriction has not been achieved in adults or children with chronic renal failure. Very low phosphate diets are unpalatable, and oral aluminium compounds used to bind dietary phosphate to prevent absorption carry a risk of aluminium toxicity, particularly in young children.⁷⁻⁸ Calcium carbonate has been used as an alternative phosphate binder,⁹⁻¹⁰ but long term clinical trials have not been reported. We studied the use of high dose phosphate binders and mild dietary phosphate restriction for the suppression of secondary hyperparathyroidism and compared aluminium hydroxide and calcium carbonate as phosphate binders in a randomised crossover study of children with chronic renal failure. The effects of the correction of secondary hyperparathyroidism on growth, renal function, and anaemia are reported.

Patients and methods

Twelve children aged 5-15 years (mean 11 years) in stable chronic renal failure were studied. They were selected for the study so that both mild renal insufficiency and severe chronic renal failure were represented. Table I summarises the clinical details of the children at the initial assessment.

The children had previously received reduced dietary protein and phosphate intakes with energy supplementation in the form of glucose polymer (Caloreen), and aluminium hydroxide had been given as a phosphate binder (mean dosage 1.3 g/day) with vitamin D supplementation as dihydrotachysterol (0.25 mg/m²/day; this form of vitamin D was routinely used in such children when the trial began, although now we prefer to use 1 α or 1,25-dihydroxycholecalciferol). Table I shows the other medications used.

Initially the aluminium hydroxide was withdrawn while the patients continued with their previous diets for three months. Three day prospective dietary assessments with accurate weighed records of all food items consumed were performed monthly over a weekend

Evelina Children's Hospital, Guy's Hospital, London SE1 9RT

R H K MAK, PHD, MRCP, Wellcome lecturer

C TURNER, BSC, biochemist

THEA THOMPSON, BSC, research dietitian

HELEN POWELL, MSC, research dietitian

G B HAYCOCK, FRCP, consultant paediatrician

C CHANTLER, MD, FRCP, professor of paediatric nephrology

Correspondence to: Professor Chantler.

(Friday, Saturday, Sunday) throughout the study, a computer program of food tables being used to analyse the results. This method of dietary assessment agrees closely with chemical analysis of duplicate samples of food consumed (for protein, $r=0.96$; 95% confidence limits -4% to $+16\%$).¹¹ Urine and faeces were collected over the same period. Blood samples were taken on the morning after completing the three day collections. Tubular reabsorption of phosphate was calculated from the formula $1-(^{10}\text{PO}_4/^{10}\text{PO}_4 \times \text{PCr}/^{10}\text{Cr})$, where $^{10}\text{PO}_4$ =urinary phosphate, $^{10}\text{PO}_4$ =plasma phosphate, ^{10}Cr =urinary creatinine, and ^{10}Cr =plasma creatinine. Theoretical phosphate threshold was calculated from tubular reabsorption of phosphate and plasma phosphate values using Bijvoet's nomograms.¹² In a separate series of experiments we found that estimation of theoretical phosphate threshold from 24 hour urine specimens compared well with the method described by Bijvoet, which utilises three hour urine collections obtained in the morning while fasting and during a moderate diuresis¹³ ($n=40$; $r=0.87$; $p<0.001$).

After the initial three months the diet was stabilised with moderate phosphorus restriction while maintaining protein intake at the previous level. The children were advised to reduce the intake of dairy protein, especially skimmed milk, cheese, and milk chocolates. Low phosphorus milk substitutes and special low phosphorus baking powder were provided. Food tables were given so that food items with a low phosphorus content could be chosen—for example, fine cereals contain less phosphate than cereals with bran. If the child had a particular liking for a food with a high phosphorus content it was allowed in moderation and the dosage of the phosphate binder used increased accordingly.

The patients were randomly allocated to receive either aluminium hydroxide or calcium carbonate as the phosphate binder. The dosage was increased to reduce the plasma phosphate concentration to the lower limit of the normal range and the children seen fortnightly until this was achieved. Further adjustments to the dosage of the phosphate binder were made from the monthly dietary assessment and based on the plasma phosphate, tubular reabsorption of phosphate, theoretical phosphate threshold, and serum parathyroid hormone results with the intention of maximising the tubular reabsorption of phosphate and theoretical phosphate threshold and reducing the parathyroid hormone concentration as far as possible to normal. Vitamin D supplementation in the form of dihydrotachysterol was provided for all children and the dosage was not changed for the six months before entry to the study and throughout the 15 months of the study period. No change in other medications occurred during the study period.

Parathyroid hormone was measured by radioimmunoassay with an antibody (BW 211/32) directed towards the whole molecule with emphasis on the N terminal.¹⁴ Urinary cyclic adenosine monophosphate was measured by competitive protein binding assay (Amersham International).¹⁵ Plasma and urinary calcium, phosphate, alkaline phosphatase, and creatinine values were measured by a multichannel autoanalyser (Vickers). Ten per cent hydrochloric acid (50 ml) was added to each urine bottle to prevent phosphorus precipitating during the collection. Faeces were digested with concentrated sulphuric acid using a selenium catalyst and assayed for phosphate using the phosphomolybdate reaction.¹⁶

Transiliac bone biopsy was performed in all patients with an 8 mm Bordier needle under a short general anaesthetic before and after 12

months of treatment. Qualitative analysis was performed blindly by a single observer and grades of definite improvement, deterioration, and no appreciable change given. Glomerular filtration rate was measured by the chromium-51 edetic acid method using single exponential analysis.¹⁷ Estimated glomerular filtration rate¹⁸ was calculated from the formula $40 \times \text{height (cm)}/\text{plasma creatinine } (\mu\text{mol/l})$. Height was measured with the same Stadiometer by the same single observer throughout and analysed using standard growth charts.

Statistical analysis was by paired Student's t test and the least squares method of linear regression. All values are expressed as means and standard error (SE). The study was approved by the Guy's Hospital ethical committee and informed consent obtained from the patients and parents before inclusion in the study.

Results

Table I gives the details of the 12 children studied and the results at the end of the initial three month period; all the children had raised concentrations of serum immunoreactive parathyroid hormone. Figures 1 and 2 and table II summarise the subsequent biochemical and dietary changes which occurred. Parathyroid hormone concentrations were reduced to within the normal range for children (less than 450 ng/l) by the end of six months of treatment. Urinary excretion of cyclic adenosine monophosphate (normal range 120-350 $\mu\text{mol/mol}$ creatinine; 370-1075 $\mu\text{g/g}$ creatinine), an index of parathyroid hormone activity, also fell significantly. Two of the children were less compliant towards the end of the study, and this was reflected by their

FIG 1—Changes in serum parathyroid hormone concentrations after institution of low phosphate diet with high dose phosphate binders (aluminium hydroxide (●) and calcium carbonate (○)). Points are means. Bars are SE.

TABLE I—Details of 12 children studied and results at end of initial three month period of evaluation

Case No	Age (years)	Sex	Diagnosis	Duration of renal disease (years)	Pubertal state (Tanner's score)	Height standard deviation score (bone age)*	Glomerular filtration rate (ml min ⁻¹ 1.73 m ⁻²)	Urea (mmol/l)	Parathyroid hormone (ng/l)	Theoretical phosphate threshold (mmol/l)	Haemoglobin (g/l)	Medications (other than aluminium hydroxide, vitamin D)
1	5	F	Neonatal cortical necrosis	5	1.1	+2.60	9	18.8	1500	0.62	94	Sodium bicarbonate
2	6	M	Haemolytic uraemic syndrome	1	1.1	+0.57	31	22.2	980	0.95	79	Captopril, frusemide, propranolol
3	7	M	Obstructive uropathy	7	1.1	-2.83	10	35.8	1600	0.17	96	Sodium bicarbonate, co-trimoxazole, ferrous sulphate
4	10	F	Obstructive uropathy	2	1.1	-2.10	35	13.4	750	0.68	125	Co-trimoxazole
5	10	M	Reflux dysplasia	10	1.1	-1.78	32	17.9	750	1.08	124	
6	10	F	Reflux nephropathy	1	1.1	-1.40	9	25.1	2600	0.38	73	Captopril, prazosin, frusemide, propranolol, cephalixin, Ketovite
7	10	F	Reflux nephropathy	3	2.2	+0.70	22	12.0	720	0.25	112	Sodium bicarbonate, prazosin, frusemide, propranolol, nitrofurantoin
8	13	F	Juvenile nephronophthisis	5	3.3	+0.20	15	18.5	1050	0.58	108	
9	13	M	Haemolytic uraemic syndrome	1	3.3	-0.95	17	29.8	1000	1.22	90	Captopril, prazosin, hydralazine, frusemide, propranolol
10	13	M	Interstitial nephritis	1	4.4	-0.93	45	9.2	640	0.55	112	Prednisolone, propranolol, ethambutol, rifampicin, isoniazid, pyridoxine
11	14	M	Mesangial capillary glomerulonephritis	9	4.4	-0.50	16	31.1	1200	0.82	105	Prednisolone, prazosin, frusemide, azathioprine, propranolol, Slow-K, dipyridamole, warfarin
12	14	M	Neonatal cortical necrosis	14	4.4	-0.12	8	25.8	1800	0.82	95	Frusemide, propranolol, lactulose

*Height standard deviation score (bone age) expressed as number of standard deviations above or below mean height of normal children of same bone age.

Conversion: SI to traditional units—Urea: 1 mmol/l = 6 mg/100 ml. Theoretical phosphate threshold: 1 mmol/l = 3.1 mg/100 ml.

FIG 2—Changes in values observed in 12 children during treatment with aluminium hydroxide (●) and calcium carbonate (○). Bars are means and SE.

*Expressed as number of standard deviations above or below mean height of normal children of same bone age.

Conversion: SI to traditional units—Phosphate: 1 mmol/l $\approx$ 3.1 mg/100 ml. Calcium: 1 mmol/l $\approx$ 4 mg/100 ml. Theoretical phosphate threshold: 1 mmol/l glomerular filtrate $\approx$ 3.1 mg/l glomerular filtrate. Urinary cyclic adenosine monophosphate: 1 μ mol/mol creatinine $\approx$ 3.07 μ g/g creatinine. Urea: 1 mmol/l $\approx$ 6 mg/100 ml.

TABLE II—Dietary changes. Values are means (SE in parentheses)

	Basal	6 months	12 months
Phosphate (mmol/day)	32.2 (2.5)	24.5 (2.15)*	26.5 (1.4)
Calcium (mmol/day)	17.3 (2.1)	13.0 (1.5)*	12.1 (1.0)*
Protein (% minimum recommended intake)	142 (11)	135 (7)	136 (5)
Energy (% recommended daily allowance)	92 (6)	100 (5)	101 (4)

* $p < 0.05$ compared with basal value.

Conversion: SI to traditional units—Phosphate: 1 mmol $\approx$ 31 mg. Calcium: 1 mmol $\approx$ 40 mg.

plasma phosphate, theoretical reabsorption of phosphate, and serum parathyroid hormone values.

The biochemical changes at the end of six months of treatment with either calcium carbonate or aluminium hydroxide were not significantly different apart from higher serum aluminium concentrations during treatment with aluminium hydroxide (1.1 (SE 0.2) v 3.3 (0.5) μ mol/l; 3.0 (0.6) v 9.0 (1.3) μ g/100 ml) ($p < 0.001$). Faecal and urinary phosphorus excretion expressed as a percentage of intake was not different during treatment with calcium carbonate (faecal 52 (SE 7)%; urinary 30 (4)%) and aluminium hydroxide (61 (7)%; 25 (4)%). Dosage of aluminium hydroxide was much higher at the end of treatment (5.8 (SE 0.8) g/day) compared with initial conventional doses (1.3 (0.5) g/day). Dosage of calcium carbonate was 3.4 (SE 0.6) g at the end of treatment.

Eleven of the 12 repeat bone biopsy specimens were technically satisfactory. Mild to moderate features of osteitis fibrosa with no osteomalacia were present in all the specimens at the beginning of the study. Osteitis fibrosa definitely improved in four patients (mean parathy-

roid hormone concentration: before 1300 (SE 450), after 430 (140) ng/l), deteriorated in two (mean parathyroid hormone concentrations: before 1300 (280), after 880 (130) ng/l), and did not change in five (mean parathyroid hormone concentration: before 1150 (210), after 300 (80) ng/l). No osteomalacia was apparent after treatment. The two patients in whom bone disease worsened were those who were less compliant with their phosphate control. Plasma phosphate concentration at the end of the study was 1.6 mmol/l (5.0 mg/100 ml) in both patients, whereas the mean for the rest of the group was 1.25 (SE 0.05) mmol/l (3.9 (0.15) mg/100 ml). Total phosphate excretion in the two non-compliant patients was similar to the others, but urine phosphate excretion was raised (59% and 81% compared with a mean of 28 (SE 4)% for the other patients) and faecal phosphate excretion was low (34% and 35%, mean for group 58 (7)%).

Significant increases in growth velocity standard deviation scores calculated according to bone age (-0.83 (SE 0.32) v $+0.65$ (0.42); $p < 0.01$) and chronological age (-0.82 (0.31) v $+0.31$ (0.39); $p < 0.01$) were observed before and after 12 months of treatment. Glomerular filtration rate as measured using edetic acid showed no significant changes during treatment (21 (SE 4) v 23 (5) ml/min/1.73 m²). In 10 patients in whom previous data were available there was no significant change in estimated glomerular filtration rate one year before (28.1 (SE 3.1) ml/min/1.73 m²), at the beginning (26.7 (4.1) ml/min/1.73 m²), and at the end (26.4 (4.8) ml/min/1.73 m²) of the study. Mean haemoglobin concentration (101 (SE 5) v 109 (5) g/l) did not alter before and after 12 months of treatment.

Side effects included transient periods of hypercalcaemia and hypophosphataemia, which were easily reversed by reducing the dosage of phosphate binder. There was no significant difference in the incidence of side effects during treatment with calcium carbonate or aluminium hydroxide.

Discussion

Phosphate retention in uraemia is implicated in the development of secondary hyperparathyroidism and in alterations in the metabolism of vitamin D. An increase in plasma phosphate concentration as the glomerular filtration rate falls is associated with a reduction in the plasma concentration of ionised calcium with stimulation of parathyroid hormone, and in addition phosphorus mediated suppression of renal 25-hydroxyvitamin D₃ 1 α -hydroxylase leads to a decrease in the plasma concentration of 1,25-dihydroxyvitamin D₃, which reduces both the gut absorption and bone reabsorption of calcium, also leading to stimulation of parathyroid hormone release.¹⁹ With mild renal insufficiency the increase in parathyroid hormone is enough to return the plasma phosphate concentration to normal, but severe chronic renal failure is associated with a rise in the plasma phosphate value, which may result in a high calcium $\times$ phosphate product, leading to nephrocalcinosis and rapid deterioration of renal function.²⁰ In experiments in dogs secondary hyperparathyroidism was prevented by limiting phosphate intake in proportion to the reduction in renal function in conjunction with supplementation with vitamin D.²¹ In addition, restriction of dietary phosphate in uraemic rats led to increased survival and a reduction in renal damage.²²

Low phosphate diets are unpalatable and only short term studies, limited to 60 days, in adults have been reported.²³ In four patients with mild chronic renal failure dietary phosphate restriction resulted in correction of secondary hyperparathyroidism, increased gastrointestinal absorption of calcium, and improved bone histological appearances with no change in plasma calcium, phosphate, or phosphate balance. Phosphate binders have been used extensively to prevent dietary phosphate absorption. Biswas *et al* studied the short term effects of aluminium hydroxide in adults with preterminal chronic renal failure, but, whereas serum phosphate concentrations fell with a rise in total and ionised calcium, there was no reversal of secondary hyperparathyroidism.²⁴ In this study, as indeed in routine clinical practice, the serum phosphate concentration was kept at the upper limit of the normal range while the plasma calcium concentrations were at the lower limit of the normal range in order to prevent a rise in the calcium $\times$ phosphate product with the risk of nephrocalcinosis. Probably, however, when secondary hyperparathyroidism is established a higher plasma ionised calcium concentration is required to initiate suppression,²⁵ and therefore it is logical to reduce the plasma phosphate concentration to the lower end of the normal range while allowing the plasma calcium concentration to rise. Reduction in phosphate retention will increase 1 α -hydroxylation of 25-hydroxyvitamin D₃ in the remnant kidney.¹⁹ In our study suppression of established secondary hyperparathyroidism was achieved by a simple dietary regimen of avoiding high phosphate foods in conjunction with much larger dosages of phosphate binders than are used conventionally.

Aluminium toxicity with encephalopathy and severe osteodystrophy has been reported in children with uraemia in whom the only major source of aluminium intake was from the gastrointestinal absorption of phosphate binders containing aluminium.^{8 26-28} Moriniere *et al* gave calcium carbonate to adult uraemic patients receiving haemodialysis and obtained satisfactory control of hyperphosphataemia and hyperparathyroidism with a reversal of hyperaluminemia which had resulted from treatment with aluminium hydroxide.¹⁰ The possibility that increased calcium absorption may lead to hypercalcaemia causes concern, but it would seem reasonable to substitute calcium carbonate for aluminium hydroxide after initial control of plasma phosphate concentration has been achieved. In our study episodes of hypercalcaemia were as common with aluminium hydroxide as with calcium carbonate and occurred only after several months of treatment, perhaps due to altered vitamin D metabolism resulting from control of phosphate retention.

The bone biopsy changes corresponded well to the clinical response. Definite improvement of bone disease occurred in

four patients in whom suppression of hyperparathyroidism was adequate. Although the histological picture was not normal at the end of 12 months of treatment, this represented only six months of adequate suppression of parathyroid hormone values. Bone disease deteriorated in two patients who were less compliant, and the remaining five patients with no appreciable change did not have severe degrees of bone disease at the beginning of the study.

The improved growth of the children was encouraging, but since many of the children were entering puberty the results should be interpreted cautiously. Correction of hyperparathyroidism has been reported to improve growth in children receiving haemodialysis, but control studies are not available.²⁹ Severe renal osteodystrophy contributes to growth retardation in advanced renal failure, but milder degrees of bone disease have not been shown to correlate with growth failure.^{30 31} Though we have shown that it is possible to suppress secondary hyperparathyroidism, at least over a 12 month period, it is not certain that such suppression can be maintained over a longer period. It would seem advisable to attempt to prevent the development of secondary hyperparathyroidism by control of phosphate absorption early in the development of renal insufficiency, particularly in very young children. In this respect the simple biochemical determinations such as plasma phosphate concentration and fractional phosphate excretion used in this study are easily applied and generally available.

Renal function did not change appreciably during the 15 months of the study; nevertheless, while this was encouraging, no conclusion about the effect of secondary hyperparathyroidism on renal function can be drawn because glomerular filtration rate as estimated from the plasma creatinine concentration was not significantly different 12 months before the study started in the 10 patients in whom data were available.

In conclusion, secondary hyperparathyroidism was suppressed over 12 months in children with preterminal chronic renal failure using a regimen of mild dietary phosphate restriction and high dose phosphate binders. Calcium carbonate was as effective as aluminium hydroxide as a phosphate binder and an improvement in growth was noted. The regimen was well tolerated with few and easily reversible side effects. In view of the risk of aluminium toxicity we recommend that high dose calcium carbonate should be used as the phosphate binder in patients with chronic renal failure after initial reduction of plasma phosphate with a low phosphate diet and aluminium hydroxide. We suggest that control of secondary hyperparathyroidism should be initiated early in the development of chronic renal failure when a definite rise in plasma parathyroid hormone concentration is detected or the tubular reabsorption of phosphate falls below normal. In children this may occur when the glomerular filtration rate falls below 45 ml/min/1.73 m².

We are grateful to Dr Juliet Compston, St Thomas's Hospital, London, for the assessment of bone biopsy specimens and help with the bone biopsy technique. We thank Dr P Smith, Newcastle Royal Infirmary, for performing the serum aluminium estimations. The study was supported by the Children Nationwide Medical Research Fund (National Medical Research Fund).

References

- 1 Slatopolsky E, Martin K, Hruska K. Parathyroid hormone metabolism and its potential as a uremic toxin. *Am J Physiol* 1980;239:F1-12.
- 2 Massry SG, Goldstein DA. The search for uremic toxin(s) "X" "X" = PTH. *Clin Nephrol* 1979;11:181-9.
- 3 Stickler GB, Bergen BJ. A review: short stature in renal disease. *Pediatr Res* 1973;7:978-82.
- 4 Slatopolsky E, Caglar S, Penell JP, *et al*. On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. *J Clin Invest* 1971;50:492-9.
- 5 Slatopolsky E, Caglar S, Gradowska J, *et al*. On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using proportional reduction of dietary phosphorus intake. *Kidney Int* 1972;2:147-52.
- 6 Kaplan MA, Canterbury JM, Bourgoigne JJ, *et al*. Reversal of hyperparathyroidism in response to dietary phosphorus restriction in the uremic dog. *Kidney Int* 1978;15:43-8.
- 7 Poisson M, Masmaly R, Lebkiri B. Dialysis encephalopathy: recovery after interruption of aluminium intake. *Br Med J* 1978;ii:1610-1.
- 8 Andreoli SP, Bergstein JM, Sherrard DJ. Aluminium intoxication from alu-

- minium containing phosphate binders in children with azotemia not undergoing hemodialysis. *N Engl J Med* 1984;**310**:1079-84.
- 9 Clarkson EM, McDonald SJ, De Wardener HE. The effect of a high intake of calcium carbonate in normal subjects and patients with chronic renal failure. *Clin Sci* 1966;**30**:425-38.
 - 10 Moriniere PH, Roussel A, Tahiri Y, et al. Substitution of aluminium hydroxide by high doses of calcium carbonate in patients on chronic haemodialysis: disappearance of hyperalumininaemia and equal control of hyperparathyroidism. *Proc Eur Dial Transplant Assoc* 1982;**19**:784-7.
 - 11 Brown HE. The evaluation of a new diet for children on haemodialysis programmes. University of London, 1976:15. (MSc thesis.)
 - 12 Walton RJ, Bijvoet OLM. Nomogram for the derivation of renal threshold phosphate concentration. *Lancet* 1975;ii:309-19.
 - 13 Bijvoet OLM. Indices for the measurement of the renal handling of phosphate. In: Massry SG, Fleisch H, eds. *Renal handling of phosphate*. New York: Plenum Medical Book Co, 1980:1-37.
 - 14 Woo J, Singer FR. Radioimmunoassay for human parathyroid hormone. *Clin Chim Acta* 1974;**54**:161-8.
 - 15 Tovey KC, Oldham KG, Whelan JAM. A simple direct assay for cyclic AMP in plasma and other biological samples using an improved competitive protein binding technique. *Clin Chim Acta* 1974;**56**:221-34.
 - 16 Lawrence R. Assay of serum inorganic phosphate without deproteinisation: automated and manual micromethods. *Ann Clin Biochem* 1974;**11**:234-6.
 - 17 Chantler C, Barratt TM. Estimation of glomerular filtration rate from plasma clearance of 51-chromium edetic acid. *Arch Dis Child* 1972;**47**:613-7.
 - 18 Counahan R, Chantler C, Ghazali S, et al. Estimation of glomerular filtration rate from plasma creatinine concentration in children. *Arch Dis Child* 1976;**51**:875-8.
 - 19 Portale AA, Booth BE, Halloran BP, et al. Effect of dietary phosphorus on circulating concentrations of 1,25 dihydroxy vitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. *J Clin Invest* 1984;**73**:1580-9.

- 20 Bricker NS. On the pathogenesis of the uremic state: an exposition of the "trade-off hypothesis." *N Engl J Med* 1972;**286**:1093-9.
- 21 Rutherford WE, Bordier P, Marie P, et al. Phosphate control and 25 hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog. *J Clin Invest* 1977;**60**:332-41.
- 22 Ibels LS, Alfrey AC, Haut L, et al. Preservation of function in experimental renal disease by dietary restriction of phosphate. *N Engl J Med* 1978;**298**:122-6.
- 23 Llach F, Massry SG, Koffler A, et al. Secondary hyperparathyroidism in early renal failure: role of phosphate retention (Abstract). *Clin Res* 1977;**25**:507A.
- 24 Biswas CK, Arze RS, Ramos JM, et al. Effect of aluminium hydroxide on serum ionized calcium, immunoreactive parathyroid hormone, and aluminium in chronic renal failure. *Br Med J* 1982;**284**:776-8.
- 25 Brown EM, Wilson RE, Eastman RC, Pallotta J, Marynick S. Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. *J Clin Endocrinol Metab* 1982;**54**:172-9.
- 26 Nathan E, Pedersen S. Dialysis encephalopathy in a non-dialysed uraemic boy treated with aluminium hydroxide orally. *Acta Paediatr Scand* 1980;**69**:793-6.
- 27 Groszold WR, Reznik V, Mendoza A, et al. Accumulation of aluminium in a non-dialysed uraemic child receiving aluminium hydroxide. *Pediatrics* 1983;**71**:56-8.
- 28 Sedman AB, Miller NL, Warady BA, Lunn GM, Alfrey AC. Aluminium loading in children with chronic renal failure. *Kidney Int* 1984;**26**:201-4.
- 29 Broyer M, Kleinknecht C, Lorient C, et al. Growth in children treated with long term hemodialysis. *J Pediatr* 1974;**84**:642-9.
- 30 Hodson EM, Shan PF, Evans RA, et al. Growth retardation and renal osteodystrophy in children with chronic renal failure. *J Pediatr* 1983;**103**:735-40.
- 31 Norman ME, Mazur AT, Borden IVS, et al. Early diagnosis of juvenile renal osteodystrophy. *J Pediatr* 1980;**97**:226-31.

(Accepted 11 June 1985)

Simple mechanical methods for cardioversion: defence of the precordial thump and cough version

G CALDWELL, G MILLAR, ELIZABETH QUINN, R VINCENT, D A CHAMBERLAIN

Abstract

A prospective study was made of the value of the precordial thump and of cough version in life threatening ventricular arrhythmias. Of about 5000 medical and surgical patients, 68 were treated for persistent ventricular tachycardia and 248 for ventricular fibrillation, 86 of whom had presented outside hospital. Mechanical intervention was successful in 26 incidents occurring in 23 patients. Electrocardiographic records were obtained in 14 instances. Ventricular fibrillation was terminated by a thump in five patients and ventricular tachycardia by either a thump or a cough in a total of 17 patients. Four additional instances were recorded of successful recovery from asystolic or unspecified circulatory arrest after a precordial thump. Fifteen patients survived to be discharged from hospital.

The potential benefit of the precordial thump and cough versions greatly outweighs their risks; hence these manoeuvres should probably be reintroduced into schedules for first aid resuscitation.

Introduction

Mechanical methods for treating cardiac arrest first attracted attention in 1920, when Schott reported that a blow to the chest restored the heart beat in a patient with an Adams-Stokes attack.¹

More recent reports have described both precordial thumps² and coughing³ for the reversion of ventricular tachycardia; precordial thumps may also be effective in ventricular fibrillation.^{4,5}

Precordial thumps were once recommended widely, but then awareness grew of the possible risk of converting ventricular tachycardia to ventricular fibrillation by such manoeuvres.⁵ The American Heart Association now recommends a precordial thump only at the onset of ventricular tachycardia or fibrillation for patients who are being monitored.⁶ This manoeuvre has been deleted entirely from British first aid manuals.⁷

Evidence for the effectiveness of these physical manoeuvres is often anecdotal. Moreover, the lack of electrocardiographic proof of their success has generated further scepticism. We therefore report our experience of cough and thump version documented as fully as possible in a prospective study carried out over one year from May 1983.

Patients and methods

The population studied comprised all patients—about 5000—admitted to the cardiac care unit, the intensive care unit, or the general medical and surgical wards of this hospital together with any victim of sudden death occurring outside hospital in whom an attempt at resuscitation was made. Of this group, a little over 1000 patients were judged to be at risk of circulatory arrest.

From 1 May 1983 we recorded relevant information from all attempted resuscitations associated with ventricular tachycardia or fibrillation. Whenever possible electrocardiograms were obtained during resuscitation, but in many cases recordings could not be continued during therapeutic interventions.

Patients who were unconscious with cardiac arrest were given a precordial thump over the lower sternum. The initial treatment for ventricular tachycardia, or for ventricular fibrillation of recent onset in patients who were still conscious, was an instruction to cough. If this was unsuccessful a precordial thump was used after explanation to the patient. Subsequent treatment was continued on conventional lines with electrical cardioversion and drugs as appropriate.

We did not measure the force required for the precordial thump, but our practice was to give as firm a blow as possible from a height of 15 to 20 cm above the chest, directed at a point two thirds of the way down the sternum.

Royal Sussex County Hospital, Brighton, East Sussex BN2 5BE

G CALDWELL, BA, MRCP, registrar in medicine

G MILLAR, resuscitation technician

ELIZABETH QUINN, research assistant

R VINCENT, MD, FRCP, consultant cardiologist

D A CHAMBERLAIN, MD, FRCP, consultant cardiologist

Correspondence to: Dr Chamberlain.